DK1196196T3 - Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer - Google Patents

Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer

Info

Publication number
DK1196196T3
DK1196196T3 DK00954335.6T DK00954335T DK1196196T3 DK 1196196 T3 DK1196196 T3 DK 1196196T3 DK 00954335 T DK00954335 T DK 00954335T DK 1196196 T3 DK1196196 T3 DK 1196196T3
Authority
DK
Denmark
Prior art keywords
membrane
cell
compartment
specific
mediating
Prior art date
Application number
DK00954335.6T
Other languages
English (en)
Inventor
Ruediger Pipkorn
Waldemar Waldeck
Juergen Debus
Peter Peschke
Eckart Friedrich
Klaus Braun
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK1196196T3 publication Critical patent/DK1196196T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Fishing Rods (AREA)
DK00954335.6T 1999-07-16 2000-07-14 Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer DK1196196T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19933492A DE19933492B4 (de) 1999-07-16 1999-07-16 Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
PCT/DE2000/002346 WO2001005432A2 (de) 1999-07-16 2000-07-14 Konjugat zur vermittlung eines zell-, kompartiment- oder membranspezifischen transports von wirksubstanzen

Publications (1)

Publication Number Publication Date
DK1196196T3 true DK1196196T3 (da) 2011-01-10

Family

ID=7915084

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00954335.6T DK1196196T3 (da) 1999-07-16 2000-07-14 Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer

Country Status (9)

Country Link
US (1) US6821948B1 (da)
EP (1) EP1196196B8 (da)
JP (1) JP2003504417A (da)
AT (1) ATE480261T1 (da)
AU (1) AU773842B2 (da)
CA (1) CA2379346C (da)
DE (2) DE19933492B4 (da)
DK (1) DK1196196T3 (da)
WO (1) WO2001005432A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10133307A1 (de) 2001-07-12 2003-02-06 Deutsches Krebsforsch PNA-Konjugat zur Therapie von mit HIV in Zusammenhang stehenden Erkrankungen
US7682669B1 (en) * 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
DE10154827A1 (de) * 2001-11-08 2003-05-28 Deutsches Krebsforsch PNA-Konjugat zur Therapie der chronischen myeloischen Leukämie (CML)
DE10154830A1 (de) * 2001-11-08 2003-06-12 Deutsches Krebsforsch Konjugat zur BNC-Therapie von strahlenresistenten Tumoren
DE10154831A1 (de) * 2001-11-08 2003-06-05 Deutsches Krebsforsch PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen
DE10158331A1 (de) * 2001-11-28 2003-06-12 Deutsches Krebsforsch Klammer-PNA-Konjugat zum spezifischen Transport thermisch aktivierbarer Nukleinsäuren
DE10201862A1 (de) * 2002-01-18 2003-08-07 Deutsches Krebsforsch Konjugat zur Behandlung prokaryontischer Infektionen
EP1329227A1 (en) * 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
EP1424343A1 (en) 2002-11-29 2004-06-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptide Conjugate useful for cell nucleus molecular imaging and tumor therapy
US8283444B2 (en) 2003-10-24 2012-10-09 Wake Forest University Non-viral delivery of compounds to mitochondria
WO2007132481A2 (en) * 2006-05-12 2007-11-22 Bharat Biotech International Limited Novel thrombolytic molecules and a process therefor
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6478632B2 (ja) * 2011-05-05 2019-03-06 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
JP6189829B2 (ja) 2011-05-13 2017-08-30 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ Ｚｓｃａｎ４とｚｓｃａｎ４依存性遺伝子を利用した体細胞の直接的な再プログラム化
US9095624B2 (en) 2011-05-23 2015-08-04 Contango Partners Group, Inc. Modular transport platform for targeted delivery of therapeutic agents
CA3176712A1 (en) 2013-03-15 2014-09-18 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejunevating human cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
RU2066552C1 (ru) * 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
EP1068338A2 (en) * 1998-03-06 2001-01-17 Oxford Biomedica (UK) Limited Enhanced prodrug activation
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2787793B1 (fr) * 1998-12-24 2001-03-23 Inst Nat Sante Rech Med Composes pseudopeptidiques dotes d'une activite inhibitrice a l'egard des voies activees par les proteines a activite tyrosine kinase et les compositions pharmaceutiques les contenant
EP1165819A2 (en) 1999-03-31 2002-01-02 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2000061617A2 (en) * 1999-04-12 2000-10-19 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Also Published As

Publication number Publication date
ATE480261T1 (de) 2010-09-15
CA2379346C (en) 2011-05-10
WO2001005432A2 (de) 2001-01-25
EP1196196B1 (de) 2010-09-08
EP1196196A2 (de) 2002-04-17
CA2379346A1 (en) 2001-01-25
EP1196196B8 (de) 2011-03-30
WO2001005432A3 (de) 2001-12-06
DE50015987D1 (de) 2010-10-21
DE19933492B4 (de) 2008-01-10
AU6683900A (en) 2001-02-05
AU773842B2 (en) 2004-06-10
JP2003504417A (ja) 2003-02-04
DE19933492A1 (de) 2001-01-18
US6821948B1 (en) 2004-11-23

Similar Documents

Publication Publication Date Title
DK1196196T3 (da) Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
DK1702079T3 (da) Fremgangsmåde til at binde oligonucleotider og peptider til faste bærere ved anvendelse af 2,4-hydrazin-(1,3,5)triazin-aktiverede faste faser
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
TR200200008T2 (tr) Fenofibratı ihtiva eden farmasötik bileşim ve bu bileşimin hazırlanması için yöntem
BR0009721A (pt) Inibidores de tirosina quinase de proteìna cìclica
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
NO20035597D0 (no) Forbedrede chelator-konjugater
DE50114213D1 (de) Verschliessen von bakterienghosts
TR200003390T2 (tr) 2-(2-Metilfenil)-3,4-dihidro-2H-pirol türevleri
DE69726674T2 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
DK1017684T3 (da) Kontrastmiddel til afbildning af infarkter og nekroser
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
EE04833B1 (et) Meetod suukaudselt manustatava, Tolperisoni või selle soola sisaldava farmatseutilise preparaadi valmistamiseks
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
HK1052007A1 (en) Novel heterocyclic derivatives, preparation methodand pharmaceutical compositions containing same.
MEP56408A (en) Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
ATE317695T1 (de) Parenterale lösung enthaltend amiodaron
TR200301650T4 (tr) Ziraat ve bahçecilikte kullanım için okzim O-eter bileşikleri ve fungusitler
TR200202195T2 (tr) 5-Yer değiştirmiş 1-(4-florofenil)-1,3- dihidroizobenzofuran'ın adım adım alkillenmesi
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
ES2195033T3 (es) Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
DK1171444T3 (da) Pyridothienodiazepiner, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse